Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies

NCT03329950 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT03329950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03329950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Lead sponsor
Celldex Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
December 1, 2017
Completion date
September 13, 2022
Enrollment
132 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

bladder urothelial carcinoma, breast cancer, cholangiocarcinoma, colorectal cancer, diffuse large b-cell lymphoma (dlbcl), esophageal cancer, fallopian tube cancer, follicular lymphoma, gastric cancer, head and neck cancer, hepatic cancer, indolent b-cell lymphomas, lymphoplasmacytic lymphoma, mantle cell lymphoma, marginal zone lymphoma, melanoma, mucosa associated lymphoid tissue, non-hodgkin lymphoma, non-small cell lung cancer, other solid tumors, ovarian cancer, pancreatic adenocarcinoma, primary peritoneal cancer, renal cell carcinoma, small lymphocytic leukemia, waldenstrom's disease